about
Monoamine oxidase B inhibitors versus other dopaminergic agents in early Parkinson's diseaseRasagiline for levodopa-induced motor complications in Parkinson´s diseasePiribedil for levodopa-induced complications in Parkinson's diseasePiribedil for symptomatic management of Parkinson's diseasePiribedil versus levodopa in early Parkinson's diseaseMonoamine oxidase B inhibitors for early Parkinson's diseaseMonoamine oxidase B inhibitors for early Parkinson's diseaseParkin functions as an E2-dependent ubiquitin- protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1Polo-like kinase 2 regulates selective autophagic α-synuclein clearance and suppresses its toxicity in vivoNeuroprotection by spice-derived nutraceuticals: you are what you eat!COMT inhibition with tolcapone in the treatment algorithm of patients with Parkinson's disease (PD): relevance for motor and non-motor featuresThalamocortical dysrhythmia: A neurological and neuropsychiatric syndrome characterized by magnetoencephalographySerum antibodies from Parkinson's disease patients react with neuronal membrane proteins from a mouse dopaminergic cell line and affect its dopamine expressionChaperone-Mediated Autophagy and Mitochondrial Homeostasis in Parkinson's DiseaseUbiquitin phosphorylation in Parkinson's disease: Implications for pathogenesis and treatmentEpigenetic Research of Neurodegenerative Disorders Using Patient iPSC-Based ModelsElectron Transport Disturbances and Neurodegeneration: From Albert Szent-Györgyi's Concept (Szeged) till Novel Approaches to Boost Mitochondrial BioenergeticsShaping action sequences in basal ganglia circuitsMetabolomics of oxidative stress in recent studies of endogenous and exogenously administered intermediate metabolitesToward Automating Clinical Assessments: A Survey of the Timed Up and GoPoly (ADP-ribose) in the pathogenesis of Parkinson's diseaseNeural stem cells could serve as a therapeutic material for age-related neurodegenerative diseasesInhibitors of MAO-A and MAO-B in Psychiatry and NeurologyRole of NMDA Receptor-Mediated Glutamatergic Signaling in Chronic and Acute NeuropathologiesTherapeutic potential of optogenetic neuromodulationParkin cleaves intracellular alpha-synuclein inclusions via the activation of calpainEffects of 6-hydroxydopamine exposure on motor activity and biochemical expression in zebrafish (Danio rerio) larvaeTherapeutic effect of hydrogen sulfide-releasing L-Dopa derivative ACS84 on 6-OHDA-induced Parkinson's disease rat modelAn update on the connections of the ventral mesencephalic dopaminergic complex.Value of genetic models in understanding the cause and mechanisms of Parkinson's diseaseQuantification and recognition of parkinsonian gait from monocular video imaging using kernel-based principal component analysis.Treatment of advanced Parkinson's diseaseInvestigating neural correlates of behavior in freely behaving rodents using inertial sensorsDJ-1 isoforms in whole blood as potential biomarkers of Parkinson diseaseConditional expression of Parkinson's disease-related R1441C LRRK2 in midbrain dopaminergic neurons of mice causes nuclear abnormalities without neurodegenerationNew MRI Biomarkers Advance the Characterization of Parkinson Disease.Alterations of diffusion tensor MRI parameters in the brains of patients with Parkinson's disease compared with normal brains: possible diagnostic use.Pathological cerebral oscillatory activity in Parkinson's disease: a critical review on methods, data and hypotheses.Entacapone.Comparison of unilateral and bilateral intrastriatal 6-hydroxydopamine-induced axon terminal lesions: evidence for interhemispheric functional coupling of the two nigrostriatal pathways.
P2860
Q24240186-E0A25C10-7402-4A5F-99F1-95924D6551D7Q24243502-5F59C213-7AD8-44EC-A7CF-C37C0D7DADCEQ24244549-9114F1B5-7569-4235-908C-B5D92D77B293Q24244952-F36CD811-B584-46F8-9F32-0DE816BABE5EQ24244961-BB1D8AFE-7D8F-40B5-BA8A-1E2A045C0393Q24246514-E1D51834-9ADF-4502-88C8-6A6F5C109534Q24246891-A4751C8D-3DFD-478D-BF54-CAFBCFF19923Q24290518-E6B89FFB-0021-4126-AF5B-FFABBE3CEAA3Q24320103-C5F52A3A-16AF-4780-B5DB-74056D8FE279Q24635358-0C8AE22B-05B4-4C7B-B896-B143D6BF917EQ24644555-4873F99E-3381-40AD-B14E-58900EC30AD7Q24655665-CD1409C3-3FA8-4400-A083-37D251907E7BQ25257546-EA1EDBF2-113E-41C2-9BD3-02367258F523Q26740364-92D5A66C-8ADA-4E7F-8E89-A48957C84196Q26770342-BD6884DF-17F2-4116-B638-C1A583F84C13Q26772307-E7DBEC7E-0D40-473C-9884-2DA62FFD01EBQ26795417-2D12DC1A-D053-4C43-99B7-237F88195730Q26799247-D8C6B1BD-5F57-4112-9C5A-D3B4659571C5Q26824720-17A4825F-56F5-4085-887E-5A6ACDC0D7EEQ26999065-868DFCF4-D9BA-4E79-BA4E-A31E211A13BFQ27005667-A1A21A2B-DD29-4686-8035-2B72FD49E924Q27021719-0533EAF6-8120-4EF9-8A68-D05DFF45FEEDQ28069609-EE46A7D4-F674-49B7-9526-7B044E357EE3Q28072353-707BD215-2A96-4946-8E9A-7467FFE861ABQ28084334-2E0AF071-B0DC-4EE1-BDDA-5E9A562C4FF5Q28201602-6634E59B-9787-4542-A0FE-5EB7247A3ED0Q28468677-CDA3CF51-F26E-479E-9C49-ACD55B6C3928Q28485947-37F99F2C-96B0-42F7-AC2B-A56BDB86C851Q30401219-3460246E-78BC-4B4B-BBCF-60FB82A5F544Q30412016-A0894793-6227-4CEE-AC53-71161069288DQ30426874-EEF379C1-0B39-46C5-997F-476DBDCC2234Q30476968-5AB09C33-2B87-478C-ACC3-D5AA07282B87Q30495497-88AFFB10-BFCE-42B6-AAE6-8B5B5B98FBFAQ30529658-B1DD2C05-B434-41D0-8DDB-A09D06A38962Q30653185-DDEC5EBE-C966-46A4-BCD7-6047441538CEQ30835312-7ECD1408-9F40-4C9B-8501-49BBD730B430Q31053308-3BD36ABE-86D2-48C5-9A78-6BAE92B4292EQ31127268-0A729BAE-2D32-4D1B-A12B-3E3C0E691761Q31440112-E5E1673F-8469-47A7-AF3C-04878532B564Q32160990-2BA28FBF-79BF-4642-81E0-1BC6C0B126A7
P2860
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh
1998年學術文章
@zh-hant
name
Parkinson's disease. Second of two parts.
@en
type
label
Parkinson's disease. Second of two parts.
@en
altLabel
Parkinson's Disease
@en
prefLabel
Parkinson's disease. Second of two parts.
@en
P1476
Parkinson's disease. Second of two parts.
@en
P2093
P304
P356
10.1056/NEJM199810153391607
P407
P577
1998-10-01T00:00:00Z